A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study

Conclusions A combination of FTD/TPI 35 mg/m2 bid on days 1 –5 and 15–19 and oxaliplatin 85 mg/m2 on days 1 and 15 every 4 weeks could be a suitable regimen for the recommended dose of FTD/TPI plus oxaliplatin in patients with refractory mCRC.

http://link.springer.com/10.1007/s10637-019-00749-9

Source: Investigational New Drugs - March 5, 2019 Category: Drugs & Pharmacology Source Type: research